Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers.

Gabrielle Jongeneel Marjolein J E Greuter Natalia KunstFelice N van ErningMiriam KoopmanJan P MedemaLouis VermeulenJan Nicolaas Maria IJzermans Geraldine R VinkCornelis J A PuntVeerle M H Coupé

Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2021)

Future research is needed to eliminate decision uncertainty driven by molecular markers.

Keyphrases

early stage
single molecule
current status
combination therapy
replacement therapy